Market capitalization | $32.54m |
Enterprise Value | $34.09m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.87 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-10.05m |
Free Cash Flow (TTM) Free Cash Flow | $-6.65m |
Cash position | $530.00k |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
1 Analyst has issued a forecast Coeptis Therapeutics:
1 Analyst has issued a forecast Coeptis Therapeutics:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -1.04 -1.04 |
4%
4%
|
|
EBITDA | -9.02 -9.02 |
56%
56%
|
EBIT (Operating Income) EBIT | -10 -10 |
53%
53%
|
Net Profit | -11 -11 |
49%
49%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company. It develops innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.
Head office | United States |
CEO | David Mehalick |
Employees | 7 |
Founded | 2017 |
Website | www.coeptistx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.